Glutathione peroxidase Inhibitors
3 drugsAbout Glutathione peroxidase
Glutathione peroxidase (GPx) enzymes protect cells from oxidative stress by catalyzing the reduction of reactive oxygen species using glutathione. This detoxification process is crucial for maintaining cellular integrity and preventing damage that can lead to various diseases.
GPx represents a potential drug target due to its role in managing oxidative stress, though no genetic evidence currently links GPx directly to specific diseases. Targeting GPx may offer therapeutic interventions related to oxidative stress management.
Three FDA-approved small molecule drugs (Selenious Acid, Multrys, and Tralement) target GPx, all approved by AM REGENT. These drugs are classified in the 'other' therapeutic area, suggesting niche applications.
Top Glutathione peroxidase Drugs
AM REGENT is the only company with approved drugs targeting GPx.
Low competition may present an opportunity for new entrants, but also indicates potential challenges in the target's viability.
Glutathione peroxidase Drug Modality Landscape
Modalities
Routes of Administration
Glutathione peroxidase is druggable by small molecules, though no oral formulations are currently approved.
The exclusive use of small molecules suggests an opportunity to explore alternative modalities like biologics.
Glutathione peroxidase Clinical Trials 45 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Glutathione peroxidase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 3 | 1 | 0 | 75% |
| Phase 2 | 15 | 11 | 0 | 4 | 100% |
| Phase 3 | 11 | 9 | 0 | 2 | 100% |
| Phase 4 | 15 | 12 | 2 | 1 | 86% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Glutathione peroxidase Drug Approval Timeline (2020 - 2020)
The first GPx-targeting drug was approved in 2019, with the most recent in 2020.
The recent approvals suggest renewed interest, but the short timespan may indicate limited long-term potential.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 38 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Glutathione peroxidase. A trial counts if an approved drug acting on Glutathione peroxidase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.